RECURSION PHARMACEUTICALS INC. - CLASS A COMMON S

Recursion to Participate in Upcoming Investor Conferences

06 May 2025 05:00:01 By Nasdaq GlobeNewswire

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

05 May 2025 03:00:00 By Nasdaq GlobeNewswire

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

04 May 2025 09:45:00 By Nasdaq GlobeNewswire

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

28 Apr 2025 05:27:07 By Nasdaq GlobeNewswire

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

22 Apr 2025 17:34:16 By Nasdaq GlobeNewswire

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

09 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

08 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conference

01 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

18 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

28 Feb 2025 03:30:00 By Nasdaq GlobeNewswire

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

24 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City

19 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Altitude Lab Startups Raise $154M in Capital

18 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

05 Feb 2025 14:24:48 By Nasdaq GlobeNewswire

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

07 Jan 2025 06:15:00 By Nasdaq GlobeNewswire

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

06 Jan 2025 05:30:00 By Nasdaq GlobeNewswire

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

20 Dec 2024 13:05:00 By Nasdaq GlobeNewswire

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

09 Dec 2024 15:00:00 By Nasdaq GlobeNewswire

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

03 Dec 2024 05:30:00 By Nasdaq GlobeNewswire

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

20 Nov 2024 04:00:00 By Nasdaq GlobeNewswire